Zoetis Inc Stock Today

ZTS Stock  USD 190.08  0.20  0.11%   

Performance

6 of 100

 
Weak
 
Strong
Modest

Odds Of Distress

Less than 6

 
High
 
Low
Low
Zoetis is selling for under 190.08 as of the 11th of October 2024; that is 0.11 percent decrease since the beginning of the trading day. The stock's lowest day price was 189.72. Zoetis has only a 6 % chance of going through financial distress over the next few years but had a somewhat modest performance during the last 90 days. Note, on August 21, 2024, Representative Jared Moskowitz of US Congress acquired under $15k worth of Zoetis Inc's common stock.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
1st of February 2013
Category
Healthcare
Classification
Health Care
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. The company was founded in 1952 and is headquartered in Parsippany, New Jersey. Zoetis Inc operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on New York Stock Exchange. The company has 453.05 M outstanding shares of which 5.1 M shares are at this time shorted by investors with about 2.63 days to cover. More on Zoetis Inc

Moving together with Zoetis Stock

  0.63A Agilent Technologies Fiscal Year End 18th of November 2024 PairCorr
  0.76DMAC DiaMedica TherapeuticsPairCorr

Moving against Zoetis Stock

  0.72VALN Valneva SE ADRPairCorr
  0.67VCEL Vericel Corp OrdPairCorr
  0.58ME 23Andme HoldingPairCorr
  0.58VCNX VaccinexPairCorr
  0.58VERV Verve TherapeuticsPairCorr
  0.5VANI Vivani MedicalPairCorr

Zoetis Stock Highlights

ESG Sustainability
Environmental
Governance
Social
CEOKristin Peck
Thematic Ideas
(View all Themes)
Old NameZetes Industries SA
Business ConcentrationPharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NYSE Composite, SP 500 Index, ARCA Pharmaceutical, Obamacare Repeal, SRI Sustainable Growth, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors)
Excise Tax ActivitiesAnimal Testing
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Return On Assets0.170.1641
Sufficiently Up
Slightly volatile
Asset Turnover0.680.5981
Fairly Up
Slightly volatile
Gross Profit Margin0.520.6828
Way Down
Pretty Stable
Net Debt3.4 B4.8 B
Way Down
Slightly volatile
Total Current Liabilities1.7 B1.9 B
Fairly Down
Slightly volatile
Non Current Liabilities Total5.6 B7.4 B
Way Down
Slightly volatile
Total Assets10.5 B14.3 B
Way Down
Slightly volatile
Total Current Assets4.9 B6.3 B
Way Down
Slightly volatile
Total Cash From Operating Activities1.3 B2.4 B
Way Down
Slightly volatile
Debt Levels
Zoetis can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Zoetis' financial leverage. It provides some insight into what part of Zoetis' total assets is financed by creditors.
Liquidity
Zoetis Inc has 6.8 B in debt with debt to equity (D/E) ratio of 1.48, which is OK given its current industry classification. Zoetis Inc has a current ratio of 2.14, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Note however, debt could still be an excellent tool for Zoetis to invest in growth at high rates of return.

Other Non Cash Items

29.45 Million
Zoetis Inc (ZTS) is traded on New York Stock Exchange in USA. It is located in 10 Sylvan Way, Parsippany, NJ, United States, 07054 and employs 14,100 people. Zoetis is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a total capitalization of 86.21 B. Zoetis Inc runs under Pharmaceuticals sector within Health Care industry. The entity has 453.05 M outstanding shares of which 5.1 M shares are at this time shorted by investors with about 2.63 days to cover. Zoetis Inc has about 3.58 B in cash with 2.35 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.88.
Check Zoetis Probability Of Bankruptcy
Ownership Allocation
Zoetis Inc retains a total of 453.05 Million outstanding shares. The majority of Zoetis outstanding shares are owned by institutional investors. These institutions are usually referred to as non-private investors looking to purchase positions in Zoetis Inc to benefit from reduced commissions. Consequently, other corporate entities are subject to a different set of regulations than regular investors in Zoetis Inc. Please pay attention to any change in the institutional holdings of Zoetis Inc as this could imply that something significant has changed or is about to change at the company. Please note that on August 21, 2024, Representative Jared Moskowitz of US Congress acquired under $15k worth of Zoetis Inc's common stock.
Check Zoetis Ownership Details

Zoetis Stock Institutional Holders

InstituionRecorded OnShares
Wells Fargo & Co2024-06-30
6.5 M
Northern Trust Corp2024-06-30
5.8 M
Norges Bank2024-06-30
M
T. Rowe Price Associates, Inc.2024-06-30
4.8 M
Nuveen Asset Management, Llc2024-06-30
4.8 M
Goldman Sachs Group Inc2024-06-30
4.7 M
Bank Of New York Mellon Corp2024-06-30
4.7 M
Fmr Inc2024-06-30
4.6 M
Unisphere Establishment2024-06-30
4.5 M
Vanguard Group Inc2024-06-30
41.2 M
Blackrock Inc2024-06-30
36.8 M
View Zoetis Diagnostics

Zoetis Historical Income Statement

At this time, Zoetis' Depreciation And Amortization is comparatively stable compared to the past year. Income Before Tax is likely to gain to about 3.1 B in 2024, whereas Total Revenue is likely to drop slightly above 6 B in 2024. View More Fundamentals

Zoetis Stock Against Markets

Zoetis Corporate Directors

William SteereIndependent DirectorProfile
Linda RhodesIndependent DirectorProfile
Frank DAmelioIndependent DirectorProfile
Robert ScullyIndependent DirectorProfile

Already Invested in Zoetis Inc?

The danger of trading Zoetis Inc is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Zoetis is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Zoetis. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Zoetis Inc is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.

Additional Tools for Zoetis Stock Analysis

When running Zoetis' price analysis, check to measure Zoetis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zoetis is operating at the current time. Most of Zoetis' value examination focuses on studying past and present price action to predict the probability of Zoetis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zoetis' price. Additionally, you may evaluate how the addition of Zoetis to your portfolios can decrease your overall portfolio volatility.